<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03428321</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL17_0436</org_study_id>
    <nct_id>NCT03428321</nct_id>
  </id_info>
  <brief_title>Small and Steatotic Hepatocellular Carcinoma</brief_title>
  <official_title>Small and Steatotic Hepatocellular Carcinoma : a Distinctive Radiological Variant With Improved Outcome After Percutenous Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous thermoablation in an effective local curative treatment in patients with
      cirrhosis and HCC smaller than 3 cm in diameter (BCLC 0-A).

      Around 30% of HCC patients referred for percutaneous ablation were regarded as non-feasible
      because of a difficult-at risk location or undetectable nodules.

      We used percutaneous thermoablation to treat HCC on high risk locations (subcapsular or liver
      dome) with or without lipiodol marked (for undetectable HCC).

      No clinical study has been published so far to compare percutaneous thermoablation of HCC on
      liver dome CT guided with artificial pneumothorax and lipiodol marked, and percutaneous
      thermoablation of HCC guided by ultrasonography (non subcapsular, distent form diaphragm).

      This retrospective study evaluate the overall survival, the local tumor progression or
      distant liver progression after percutaneous ablation for HCC and determine prognostic
      factors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We performed 412 percutaneous thermoablations on 238 patients for HCC between January 2015
      and November 2019.

      All thermoablation procedures were performed percutaneously under ultrasound or CT guidance,
      with ou without artificial pneumothorax or ascites, with ou without lipiodol marked.

      Purposes:

        -  Tumor response upon mRECIST criteria

        -  Progression-free survival

        -  Overall survival

        -  Local tumor progression

        -  Distent liver progression

        -  Prognostic factors
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Thermal ablations</measure>
    <time_frame>1 day</time_frame>
    <description>Evaluation of thermal ablations (radiofrequency and microwave ablation)</description>
  </primary_outcome>
  <enrollment type="Actual">238</enrollment>
  <condition>HCC</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who underwent one or several percutaneous thermoablations for HCC form January
        2015 to November 2019 at the Department of Radiology St-Eloi University Hospital -
        Montpellier School of Medicine France.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  HCC according to histological examination or Barcelona criteria

          -  BCLC0 or A

          -  Measurable targets according to mRECIST v1.1

          -  Child A or B7 cirrhosis

          -  HCC &lt; 4 cm, &lt; 3 nodules, Age ≥ 18 years

          -  No extrahepatic metastasis, no vascular invasion

          -  Performance status 0 or 1

          -  Thrombocytes ≥ 50 000/mm3, TP &gt; 50%

        Exclusion criteria:

          -  Follow-up &lt; 1month

          -  Lobar/main portal venous thrombus

          -  Abundant ascites

          -  Antecedent of bilio-digestive anastomosis or endoscopic sphincterotomy

          -  Combined treatment with embolization or chemo-embolization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BORIS GUIU, PU-PH</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microwave ablation</keyword>
  <keyword>Percutaneous thermalablation</keyword>
  <keyword>High risk location</keyword>
  <keyword>Articifial pneumothorax</keyword>
  <keyword>Lipiodol marked</keyword>
  <keyword>Prognostic factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

